Related references
Note: Only part of the references are listed.Serum DUPAN-2 could be an Alternative Biological Marker for CA19-9 Nonsecretors with Pancreatic Cancer
Kojiro Omiya et al.
ANNALS OF SURGERY (2023)
Pancreatic Adenocarcinoma, Version 2.2021
Margaret A. Tempero et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)
Randomized phase II trial of chemoradiotherapy with S-1 versus combination chemotherapy with gemcitabine and S-1 as neoadjuvant treatment for resectable pancreatic cancer (JASPAC 04).
Hirochika Toyama et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Lewis Antigen Phenotype and Survival of Patients With Pancreatic Cancer
Sohee Kwon et al.
PANCREAS (2020)
Cancer treatment and survivorship statistics, 2019
Kimberly D. Miller et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
New observations on the utility of CA19-9 as a biomarker in Lewis negative patients with pancreatic cancer
Guopei Luo et al.
PANCREATOLOGY (2018)
A Glimmer of Hope for Pancreatic Cancer
Hedy L. Kindler
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Surgical Indications of Distal Pancreatectomy with Celiac Axis Resection for Pancreatic Body/Tail Cancer
Teiichi Sugiura et al.
WORLD JOURNAL OF SURGERY (2017)
CA19-9-Low&Lewis (+) pancreatic cancer: A unique subtype
Guopei Luo et al.
CANCER LETTERS (2017)
Preoperative treatment with gemcitabine plus nab-paclitaxel is a safe and effective chemotherapy for pancreatic adenocarcinoma
B. Ielpo et al.
EJSO (2016)
Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)
Katsuhiko Uesaka et al.
LANCET (2016)
Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer Alliance for Clinical Trials in Oncology Trial A021101
Matthew H. G. Katz et al.
JAMA SURGERY (2016)
Predicting factors for unresectability in patients with pancreatic ductal adenocarcinoma
Ken-ichi Okada et al.
JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES (2014)
Neoadjuvant Chemotherapy with Gemcitabine and S-1 for Resectable and Borderline Pancreatic Ductal Adenocarcinoma: Results from a Prospective Multi-institutional Phase 2 Trial
Fuyuhiko Motoi et al.
ANNALS OF SURGICAL ONCOLOGY (2013)
Investigation of the freely available easy-to-use software 'EZR' for medical statistics
Y. Kanda
BONE MARROW TRANSPLANTATION (2013)
Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer The CONKO-001 Randomized Trial
Helmut Oettle et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Margin status, recurrence pattern, and prognosis after resection of pancreatic cancer
Teiichi Sugiura et al.
SURGERY (2013)
Serum CA19-9 is a Significant Predictor among Preoperative Parameters for Early Recurrence after Resection of Pancreatic Adenocarcinoma
Teiichi Sugiura et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2012)
Adjusting CA19-9 values to predict malignancy in obstructive jaundice: Influence of bilirubin and C-reactive protein
Gaetano La Greca et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2012)
Risk Factor of Surgical Site Infection After Pancreaticoduodenectomy
Teiichi Sugiura et al.
WORLD JOURNAL OF SURGERY (2012)
Long-Term Survival After Multidisciplinary Management of Resected Pancreatic Adenocarcinoma
Matthew H. G. Katz et al.
ANNALS OF SURGICAL ONCOLOGY (2009)
Increased Levels of Both Carbohydrate Antigen 19-9 and Duke Pancreatic Monoclonal Antigen Type 2 Reflect Postoperative Prognosis in Patients With Pancreatic Carcinoma
Kohei Shibata et al.
PANCREAS (2009)
Share Paper
